Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Adagrasib + TNO155 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Adagrasib | MRTX849|MRTX-849|MRTX 849 | KRAS G12C inhibitor 18 | Adagrasib (MRTX849) covalently binds to and stabilizes GDP-bound KRAS G12C, therefore prevents KRAS downstream signaling, resulting in tumor growth inhibition (PMID: 31658955). | |
TNO155 | TNO-155|TNO 155 | SHP2 Inhibitor 14 | TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04330664 | Phase Ib/II | Adagrasib + TNO155 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Active, not recruiting | USA | 0 |